BofA’s Hartnett says concentrated U.S. stock returns are likely to persist
Patrick John Finn, President and COO of Twist Bioscience Corp (NASDAQ:TWST), sold 3,189 shares of common stock on August 4, 2025, at a price of $28.364, for a total value of $90,452. The transaction comes as the stock trades near its 52-week low, having declined over 20% in the past week. According to InvestingPro analysis, technical indicators suggest the stock is currently in oversold territory.
Following the transaction, Finn directly owns 235,153 shares of Twist Bioscience Corp.
The sale was to cover tax withholding obligations related to the vesting of Restricted Stock Units, as mandated by Twist Bioscience’s equity incentive plans.
In other recent news, Twist Bioscience reported a notable 18% increase in revenue for Q3 2025, reaching $96.1 million. Despite the revenue growth, the company recorded an adjusted EBITDA loss of $8 million, although this marks an improvement from the previous fiscal year. In addition to financial updates, Twist Bioscience announced the appointment of Trynka Shineman Blake to its board of directors, where she will also serve on the audit committee. Blake’s previous experience includes serving as CEO of Vistaprint, where she significantly scaled the company’s revenue.
Analyst firms have made several adjustments to their price targets for Twist Bioscience. JPMorgan lowered its price target to $25 while maintaining an Underweight rating. TD Cowen also decreased its target to $36, citing adjusted fiscal year 2025 guidance due to changes in Next-Generation Sequencing revenue. Evercore ISI reduced its price target to $46, noting strong performance in the next-generation sequencing segment and solid gross margin results. These developments reflect the ongoing evaluation of Twist Bioscience’s market position and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.